Placebo SL Tablet

DRUG7 trials

Sponsors

Tonix Pharmaceuticals, Inc.

Conditions

COVID-19FibromyalgiaLong COVIDLong Haul COVIDMuscular DiseasesMusculoskeletal DiseasesMyofascial Pain SyndromesNervous System Diseases

Phase 2

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

CompletedNCT05472090

Tonix Pharmaceuticals, Inc.COVID-19, Long COVID, Long Haul COVID +1

Start: 2022-08-18End: 2023-07-27Updated: 2024-11-26

Phase 3

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia

CompletedNCT02436096

Tonix Pharmaceuticals, Inc.Fibromyalgia, Muscular Diseases, Musculoskeletal Diseases +4

Start: 2015-04-30End: 2016-09-30Updated: 2025-02-07

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

TerminatedNCT02829814

Tonix Pharmaceuticals, Inc.Fibromyalgia, Muscular Diseases, Musculoskeletal Diseases +4

Start: 2016-07-22End: 2016-09-13Updated: 2025-02-25

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD

TerminatedNCT03062540

Tonix Pharmaceuticals, Inc.PTSD

Start: 2017-03-27End: 2018-07-27Updated: 2024-05-22

A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

CompletedNCT04172831

Tonix Pharmaceuticals, Inc.Fibromyalgia

Start: 2019-12-09End: 2020-10-29Updated: 2022-08-08

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

CompletedNCT04508621

Tonix Pharmaceuticals, Inc.Fibromyalgia

Start: 2020-07-22End: 2021-11-01Updated: 2023-12-18

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia

CompletedNCT05273749

Tonix Pharmaceuticals, Inc.Fibromyalgia

Start: 2022-04-06End: 2023-11-14Updated: 2025-01-22

Related Papers

Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine.

2026-01-014 citations